
Opinion|Videos|May 2, 2025
FLAURA2 Maintenance: Key Strategies for Treatment Optimization and Patient Monitoring
Panelists discuss how FLAURA2 maintenance therapy strategies involve monitoring patients for toxicities and implementing dose modifications or schedule adjustments to improve tolerability.
Advertisement
Episodes in this series

Maintenance Therapy Strategies
Main Discussion Topics:
- Considerations when implementing the FLAURA2 regimen
- Management strategies for pemetrexed maintenance therapy
- Monitoring patients during maintenance treatment
Key Points for Physicians:
- FLAURA2 involves 4 cycles of carboplatin/pemetrexed followed by pemetrexed maintenance with osimertinib
- Key toxicities to monitor include leg edema, mucositis, and renal dysfunction
- Patient education and early intervention are crucial for managing toxicity
Notable Insights:
The flexibility to adjust maintenance therapy (dose reductions, treatment delays, or discontinuation) is an important aspect of optimizing the FLAURA2 regimen.
Clinical Significance:
Proactive monitoring and management of toxicities during maintenance therapy can help maintain treatment efficacy while preserving quality of life.
Advertisement
Related to this article

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5

